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Abstract
Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical
practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide
prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant
groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a butyrophenone
derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/
palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the
untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical
benefits and harms of haloperidol for delirium in hospice/palliative care patients.
Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol com-
menced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical ben-
efits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days
after it was commenced.
Results: Of the 119 participants included, the average dose was 2.1mg per 24 hours; 42 of 106 (35.2%) reported
benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n = 11)
and urinary retention (n = 6). Seven participants had their medication ceased due to harms (2 for somnolence and
2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days.
Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days.
Introduction
Delirium is a common and distressing symptom for 
many patients and families as the end of life ap-
proaches1,2 and if no reversible factors are present, is an in-
dicator of poor prognosis.
Haloperidol is a butyrophenone derivative and dopamine
antagonist. It is commonly prescribed for nausea, vomiting,
and delirium in hospice/palliative care.3–5 Its use in delirium
occurs despite little placebo controlled evidence that anti-
psychotic medication changes the natural history of delirium.
Although open label studies or randomized trials comparing
two antipsychotics have shown improvement of delirium
scores over time,2 this may relate to the natural history of
delirium, which is to resolve over time as precipitants are
treated and reversed. The three studies6–8 with placebo arms
have methodological problems (inadequately powered, in-
adequate allocation concealment).
Current international guidelines suggest targeted use of
antipsychotics for severe behavioral disturbance in delirium
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with cautious dosing and close monitoring.9 The potential
harms of haloperidol include: central effects (sedation, in-
somnia, restlessness, anxiety, euphoria, confusion, urinary
incontinence, grand mal seizures); cardiovascular effects
(tachycardia, hypotension, conduction irregularities); and
extrapyramidal effects (akathisia, dystonia, and persistent
tardive dyskinesia).5 More rarely, haloperidol has been re-
ported to cause neuroleptic malignant syndrome and hema-
tological abnormalities including leucopenia, leucocytosis,
and anemia. Although widely prescribed, the benefits and
harms of haloperidol for delirium have not been well quan-
tified in hospice/palliative care patients.
Much of the prescribing practice in hospice/palliative care
has been extrapolated from related areas of clinical practice
with populations that aremore readily studied. Due to limited
available evidence, an international initiative was com-
menced in 2011 to improve clinicians’ understanding of the
net clinical effects of key medicines used in hospice/palliative
care and to further informprescribing in this important area of
patient care.10 Building this evidence base is an extension of
the Phase 3 and 4 studies that have been carried out by the
Australian Palliative Care Clinical Studies Collaborative
(PaCCSC).11
Prospective data collection at agreed time points, using
standardized measures of clinical harms and benefits, for
medications that are frequently prescribed for symptom
control in hospice/palliative care patients can provide im-
portant information. This is information specific to the clinical
context of hospice/palliative care and cannot be provided by
studying other patient populations. This method of rapid re-
porting allows immediate and short-term net clinical effects
(benefits and harms) to be systematically studied during
routine care.
A new pragmatic tool for pharmacovigilance was created12
using secure Web-based technology, deidentified and un-
reidentifiable data, and a small number of set fields focusing
on a single medication for a single indication (even if there are
multiple indications for that medication in hospice/palliative
care). By aggregating data from a large number of centers each
of whom have provided data from a small number of con-
secutive participants who were commenced on haloperidol
for delirium as part of routine clinical care, the evidence base
of the real-world net effectiveness of this medication can be
established. This process minimizes the work involved for
individual clinicians, and represents a wide range of clinical
settings and service delivery models.
Methods
The aim of this study was to describe the net clinical effect
(i.e., the overall risk and benefit) of haloperidol when pre-
scribed for delirium in a consecutive, prospective cohort of
hospice/palliative care patients. All participating sites re-
ceived ethical waivers (as the work falls under quality as-
surance, quality improvement, performance monitoring,
clinical audit study type) or approval for low risk research
depending on each site’s Human Research Ethic Committee’s
assessment of this work. This meant that patients and/or
family members did not need to be approached or consent
provided for the study to proceed.
The study methods have been described in detail previ-
ously.10 An expert committee defined prespecified clinical
benefit and harm fields based on the available literature re-
lating to the use of haloperidol for delirium (Table 1). The
National Cancer Institute’s Common Toxicity Criteria for
Adverse Events (NCI CTCAE) Likert scales for grading effects
were used.13 Nonidentifying demographic and clinical data
were entered pro forma using a 128-bit encrypted Web portal
(www.caresearch.com.au). Participants were consecutive
patients at participating clinical sites started on haloperidol as
part of routine clinical care for delirium.
Data were recorded at three set time points: baseline (the
index symptom and symptoms that could reflect harm): 48
hours (index symptom (delirium) response), and 10 days
(harms) after commencing haloperidol. The NCI criteria for
delirium ask the clinician to rate overall severity of the
symptoms but also impact on activities of daily living and
other impacts (such as threats of harm to self or others; Table
2). This approach was chosen as the intention was to quantify
the degree of impact from a symptom perspective and to align
the assessment approaches of benefits and harms.
Overall benefit was defined as a 1-point reduction in the
NCI CTCAE (for example severe to moderate, moderate to
mild, mild to none) (Table 2). Harms were attributed to hal-
operidol if the criteria for NCI CTCAE were greater than a
baseline measurement at or before day 10 for that individual
participant. For harms rated as 3 or greater on the NCI
CTCAE criteria, data were collected on the Naranjo Score.
This is a questionnaire designed to determine the attribution
of an adverse drug reaction being due to the drug itself rather
than other factors. In the hospice/palliative care setting only
question 2, which explores the timing of the adverse events in
relation to the medication being commenced, is reported.14
Functional status was recorded using the Australianmodified
Karnofsky Performance Scale and comorbidities assessed
using the Charlson Comorbidity Index.15,16
Statistical methods
Univariable logistic regression model for each outcome on
key clinical and demographic parameters was undertaken,
clustering over site to account for correlated readings. Ad-
ditionally, logistic regression was performed for each out-
come on each pair of key parameters and their product term to
identify possible subgroups that were associated with out-
comes. We used multiple imputation to account for missing
data, with 20 resamples drawn. Results are reported as odds
ratios (OR) with 95% confidence intervals (CI). No adjustment
was made for multiple comparisons as the results are con-
sidered to be hypothesis generating. A p value less than 0.05
(two-tailed) is considered statistically significant. Data were
imported into Excel (Microsoft, Seattle, WA). All analyses
were performed in STATA SE version 12.1 (StataCorp, Col-
lege Station, TX).
Results
The clinical and demographic data of the study subjects are
shown in Table 1. Data were available for 119 participants
from 14 hospice/palliative care sites in four countries between
February 2012 and August 2012. Clinical sites were drawn
from consultative services, ambulatory clinics and specialist
inpatient hospice/palliative care units, reflecting the scope of








The majority of participants had cancer. Participants re-
ceived an average of 2.1mg of haloperidol per 24 hours
(standard deviation [SD] 1.6; median, 2mg; range, 0.5–8.0) in
parenteral or oral forms.
At 48 hours, 10 people had died and overall benefit was
reported in 42 of 106 participants (35.2%; CI 26.6%–44.0%) of
participants with recorded scores. (Table 3, Figs. 1 and 2). At
the end of the study, a total of 52 people had died and 55 of 67
were still on regular haloperidol.
A total of 14 of 57 participants (24.6%; CI 13.0%–36.1%;
Table 3) experienced 29 harms up to and including day 10
(Table 4). The most frequently encountered harms were
Table 2. Outcomes at Forty-Eight Hours after Commencing Haloperidol
for Delirium in Palliative Care Patients (n= 119a)
NCI CTC AE delirium scoreb at baseline (T0)
before commencing haloperidol
1 2 3 4
Subtotals 27 37 47 3
NCI CTC AEb delirium score at 48 hours (T1)
after commencing haloperidol
0 12c 7 4 1 0
1 29 12 13 4 0
2 33 5 16 11 1
3 27 0 2 24 1
4 3 0 0 3 0
5 10d 3 2 4 1
aMissing data= 5.
bNCI CTC AE National Cancer Institute Common Toxicity Criteria Adverse Events–delirium scale: 0, None; 1, Mild acute confusional state; 2,
Moderate and acute confusional state limiting instrumental activities of daily living (ADL); 3, Severe and acute confusional state limiting self-
care ADLs. Hospitalization indicated; 4, Life-threatening consequences; threats of self harm or harm to others; hospitalization indicated; 5, Death.
Delirium score: improved, n=42 (36.8%) of whom 12c (10.5%) had a total resolution of delirium; unchanged;n = 52ð45:6%Þ; worsened, n=20
(17.5%) of whom 10d (8.8%) died within 48 hours of commencing haloperidol. (A further 42 were dead by day 10 and a further 10 people by day 14).
Table 1. Baseline Clinical and Demographic Data
n (%) Median Range Mean SD
Age 118 (99) 75 34–99 73.2 12.8
Gender (male) 70 (59)
Australian-modified Karnofsky Performance Status Score 119 (100) 30 10–60 32 12.2
Charlson Comorbidity Index score 119 (100) 6 0–14 5.7 3.2
Body mass index 102 (86) 24 17–37 24.7 4.7
C-reactive protein 40 (34) 86.7 2–317 108 95.3
Calculated creatinine clearance 71 (60) 56 7–760 78.8 120.8
National Cancer Institute Common Toxicity Grading for Delirium 119 (100) 2 1–4 2.2 0
Primary life-limiting illness
Cancer 105 (88)
End-stage renal disease 1 (1)
End-stage cardiac disease 5 (4)
End-stage respiratory disease 0
End-stage hepatic disease 0
AIDS 0
Neurodegenerative disease 2 (2)
Other 6 (5)
Baseline adverse events n (%)a Severityb
median
(range)
Akathisia 13 (11) 1 (1–3)
Gait change 11 (9) 2 (1–3)
Rigidity 7 (6) 1 (1–3)
Somnolence 49 (41) 2 (1–3)
Tremor 11 (9) 1 (1–3)
Dizziness 6 (5) 1 (1–2)
Urinary retention 9 (8) 2 (1–3)
Other 2 (2) 2.5 (2-–3)
aPatients could have more than one harm.
bNational Cancer Institute’s Common Toxicity Criteria Adverse Events (NCI CTC AE).








somnolence (11; 9%) and urinary retention (6; 5%). Seven
participants had their medication ceased for harms of whom
two had somnolence and two had rigidity.
In the logistic regression analyses, the Karnofsky score
moderated the relationship between Charlson Comorbidity
Index (CCI) and benefit from haloperidol. The higher the
Karnofsky score the stronger the association between wors-
ening comorbidity (higher CCI) and poorer response. For
those with a median Karnofsky score of 30, subjects were
approximately 12% less likely to benefit with each one point
increase in CCI (OR= 0.88; CI 0.77 1.00; p= 0.043). For someone
with a Karnofsky score of 60, subjects were approximately
39% less likely to benefit with each point increase in CCI
(OR= 0.63; CI 0.43 0.99; p= 0.02). All other univariable and in-
teraction analyses did not contain terms that were significant.
Discussion
Approximately 1 in 3 participants experienced benefit at
48 hours. Approximately 1 in 15 participants stopped halo-
peridol due to harms, 4 of which were graded 4. By using a
multicenter, multinational, rapid, prospective design to re-
flect actual clinical practice, this study helps to understand
the actual performance of medications in hospice/palliative
care. The participants were mostly elderly (mean age, 73
years) and of poor physical functional status (mean AKPS
32). They had multiple comorbidities (CCI mean 5.7) prior to
commencing treatment for delirium. Despite this clinical
setting, haloperidol was relatively well tolerated in the im-
mediate and short term. Of those with a documented harm,
few were treated by a reduction in the dose or cessation of
the medication.
There is little high-quality evidence available to guide the
management of delirium in hospice/palliative care patients,
particularly as people with this condition approach the end of
their lives.16 Systematic reviews have identified only a small
number of studies, with a paucity of literature relating to the
setting of people recognized to be approaching the end of life.
However the findings of this study are consistent with sys-
tematic reviews.18–20 Haloperidol is still recommended as the
first-line agent in delirium management.16 Of note, the doses
reported by Campbell et al.18 were much greater than those
received by participants in this study (mean, 6.5mg per 24
hours compared with 2.1mg per 24 hours).
Table 3. Net Clinical Effects (Individual Patients)
Benefit/s Harm(s)
n, % (95% CI) n, % (95% CI)
(1-point NCI reduction
in delirium score over baseline)a
(1-point NCI increase
in any toxicity score over baseline)b Action following harm(s)c n (%)
Yes n = 42
(38.5% CI 29.2%, 47.8%)
No n = 13
(52.0% CI 31.0%, 73.0%)
Medication added (1), dose reduction (1) 2 (2)
Yes n= 4
(16.0% CI 0.6%, 31.4%)
Cessation 1 (1)
Dose reduction 0
No change to medication 2 (2)
Medication to treat toxicity added 1 (1)
Other 0
No action 0
Missing n = 8
(32.0% CI 12.3%, 51.6%)
Died n = 17
No n= 62
(56.8% CI 47.4%, 66.3%)
No n = 23
(57.5% CI 41.5%, 73.5%)
Ceased (1), no change (1), other (1) 3 (3)
Yes n= 9
(22.5% CI 9.0%, 36.0%)
Cessation 2 (2)
Dose reduction 1 (1)
No change to medication 5 (4)
Medication to treat toxicity added 2 (2)
Other 1 (1)
No action 0
Missing n = 8
(20.0% CI 7.0%, 33.0%)
Died n = 22
Missing n= 5
(4.6% CI 0.6%, 8.6%)
No n = 2
(66.7% CI - 76.8%, 210.0%)
Yes n= 1
(33.3% CI - 11.0.1%, 176.8%)
No change to medication 1 (1)
Died n = 2
Died n= 10
aReported at 48 hours.
bReported up until 10 days.
cA person may have more than one action.







An important change to the first of these pharmacov-
igilance studies12 was that harm was measured at baseline in
addition to T1 and T2 and only worsening over baseline is
reported. There were high baseline rates of somnolence
49 (41%), akathisia 13(11%), gait change 11(9%), and rigidity
7(6%) that may otherwise have been attributed to haloperidol.
Limitations
This study addresses only immediate and short-term
harms. Harms of prolonged haloperidol administration such
as some of the extrapyramidal effects will not be detected.
Consistency of interpretation and measurement is a challenge
for multicenter studies. This study also relies on clinicians
recognizing delirium and utilizing a rating scale that only
quantifies symptoms and some clinical impacts; rather than a
detailed delirium scale with established psychometric prop-
erties. NCI CTCAE is conceived as a high-level screening tool
for a wide range of symptoms and data are not available on its
correlationwith diagnostic tools for delirium. A project officer
provided continuing e-mail updates and an information
stream about the study to provide a central point of liaison for
participating sites (Australia, New Zealand, Canada, and the
United Kingdom).
Generalizability
Clinical sites were drawn from consultative services, am-
bulatory clinics and specialist inpatient hospice/palliative
care units, reflecting the scope of current specialist palliative
FIG. 1. Participant flow for the use of haloperidol in palliative care for delirium (n = 119; 14 sites; 4 countries). *Benefit is
defined as‡ 1-point reduction on the National Cancer Institutes’ Common Toxicity Criteria for Adverse Events (NCI CTC AE)
for delirium. **Harms are defined as ‡ 1-point increase over baseline for relevant NCE CTC AE score.
Table 4. Harms Encountered from Baseline to Ten Days (n = 119)a
Response to toxicity













n = 42a n = 62a n (%) harmsb (range)c n = 3 n = 1 n = 7 added n= 3 n = 1
Akathisia 1 2 (2) 1 (1) 2 (2–4) 1 — — 3 1
Gait change 1 1 (1) 1 (1) 3 (3) — 2 — 0
Rigidity 0 2 (2) — 3.5 (2–5) 2 — — 1 0
Somnolence 3 7 (6) 3 (3) 2 (1–4) 2 — 6 3 1
Tremor 0 2 (2) — 3 (2–4) 1 1 1 —
Dizziness 0 — — — — — — —
Urinary retention 2 3 (3) 2 (2) 2 (1–3) — 1 3 1 1
Otherd 2 1 (1) 2 (2) 2 (2–3) 1 1 2 1 0
aMissing n = 15 (see Table 3 for explanation).
bParticipants can have more than one harm but can also have more than one response.
cNational Cancer Institute’s Common Toxicity Criteria Adverse Events (NCI CTC AE).
dOther harms: dyskinetic jaw/tongue/lip movements (1), depression (1), myoclonic jerks (1), postural hypotension (1), urinary retention







care practice in the participating countries. The age range of
participants (mean age of 73 years) and predominance of
malignant diagnoses (88%) represents current referral pat-
terns for many services.
This study demonstrates that when haloperidol is used for
delirium, where the mean dose was 2.1mg per 24 hours, it is
relatively well tolerated, with relatively few immediate and
short term side-effects. An adequately powered, multi-site,
parallel arm Phase 3 double-blinded, randomized, placebo-
controlled trial evaluating the additional net benefit of halo-
peridol in treating delirium in hospice/palliative care patients
is nearing completion of accrual.
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